People: Osiris Therapeutics Inc (OSIR.O)

OSIR.O on Consolidated Issue listed on NASDAQ Global Market

8.65USD
9 Feb 2010
Price Change (% chg)

$0.12 (+1.41%)
Prev Close
$8.65
Open
--
Day's High
$8.69
Day's Low
$8.55
Volume
71,921
Avg. Vol
161,515
52-wk High
$20.96
52-wk Low
$5.35

view people for:

Summary

Name Age Since Current Position
Friedli, Peter 55 Chairman of the Board
Mills, C. Randall 37 2004 President, Chief Executive Officer, Director
Jacoby, Philip 57 2009 Chief Financial Officer, Vice President - Finance, PAO, Corporate Secretary
Debrabandere, Lode 43 2006 Vice President, General Manager - Inflammatory Diseases
Williams, Michelle 34 2007 Vice President - Development
Gutzwiller, Felix 61 2003 Director
Moyes, Jay 55 2006 Director
Barnhill, Gregory 55 2006 Director
» Insider Trading

Biographies

Name Description
Friedli, Peter Mr. Peter Friedli is Chairman of the Board of Osiris Therapeutics, Inc. and was co-founder of Osiris. Mr. Friedli has been a director of Osiris since January 1996, except for the period between February and June 2004. Since 1996, he has been a principal of the investment-banking firm Friedli Corporate Finance, Inc., a Swiss venture capital firm which has made significant investments in the biotechnology industry and has been the primary source of financing for Osiris. Mr. Friedli is also President of New Venturetec Ltd., a Swiss publicly traded investment company. Mr. Friedli has extensive experience as an independent investment manager in venture capital and has specialized in investments domiciled in the United States in the areas of biotechnology and technology. Previously, he worked in the field of international management consulting for service and industrial companies in Europe and the United States. Mr. Friedli is a director of Invenda, Inc., a publicly traded provider of interactive database marketing technologies and services. He also serves as a director in certain private companies.
Mills, C. Randall Dr. C. Randal Mills is President and Chief Executive Officer of Osiris Therapeutics, Inc since July 2004. Dr. Mills has also been a member of Board since July 2004. Prior to joining Osiris, Dr. Mills was an executive officer of Regeneration Technologies, Inc. ("RTI") (NASDAQ—RTIX). Dr. Mills served in several leadership positions at RTI from its formation in 1998 until 2004, including Vice President of Business Development and Vice President of Operations and R&D. Prior to RTI, Dr. Mills was a member of the founding management team of the University of Florida Tissue Bank, Inc., the predecessor company to RTI. Dr. Mills received a bachelor's degree in microbiology and cell science and a Ph.D. in drug development, both from the University of Florida.
Jacoby, Philip Mr. Philip R. Jacoby, Jr. is the Chief Financial Officer, Vice President - Finance, Principal Accounting Officer, Corporate Secretary of Osiris Therapeutics, Inc. He has over 30 years of financial and management experience with public and privately held companies. Mr. Jacoby joined Osiris in April 2005 as Corporate Controller and principal accounting officer in preparation for initial public offering. Prior to joining Osiris, Mr. Jacoby was the Vice President and Corporate Controller for FTI Consulting, Inc. (NYSE—FCN) from 1999 through the first quarter of 2005. Mr. Jacoby began his career with Arthur Andersen & Co. and earned his undergraduate degree in business and public administration from the University of Maryland.
Debrabandere, Lode Dr. Debrabandere is Vice President and General Manager - Inflammatory Diseases of Osiris Therapeutics, Inc. He joined the company in this capacity in July 2006. Prior to joining Osiris, Dr. Debrabandere served for over four years with Bristol-Myers Squibb as Vice President for Strategic Marketing for Neuroscience and Infectious Diseases. He led the Neuroscience Unit and was the Global Brand Leader for Abilify™. Previously, Dr. Debrabandere led the Marketing department of UCB Pharma Inc., focusing in the areas of allergy/respiratory (Zyrtec™) and neurology (Keppra™). Dr. Debrabandere earned an M.B.A., a Ph.D. in pharmaceutical sciences, toxicology, and a Pharm. D. degree in pharmaceutical sciences, all from the University of Leuven, Belgium.
Williams, Michelle Dr. Michelle LeRoux Williams, Ph.D., is Vice President - Development of Osiris Therapeutics, Inc. since October 2001. Dr. Williams previously served as Director of Orthopedics and in that role was responsible for the development of Osteocel from initial concept through market launch. Prior to joining the company, Dr. Williams completed an NIH postdoctoral fellowship in tissue engineering at Columbia University, evaluating cellular constructs for the repair and regeneration of cartilage in arthritis patients. Dr. Williams earned a bachelors degree in mechanical engineering from Rice University and a Ph.D. in biomedical engineering from Duke University.
Gutzwiller, Felix Dr. Felix Gutzwiller, M.D., Dr.P.H., has been a member of the Board of Osiris Therapeutics, Inc. since 2003, and is Professor and Chairman of the Department of Public Health of the University of Zurich Medical School. Dr. Gutzwiller is also an elected member of the Swiss Parliament. Dr. Gutzwiller received a medical degree from the University of Basel in 1974 and did his post-graduate training at both Harvard University and Johns Hopkins University. He received his Dr.P.H. from the Johns Hopkins University School of Hygiene and Public Health in 1980. Dr. Gutzwiller has received many honors and awards over the years in the health profession.
Moyes, Jay Mr. Jay M. Moyes has been a member of the Board of Osiris Therapeutics, Inc. since the completion of the initial public offering in August 2006. In May 2008, Mr. Moyes became the Chief Financial Officer of XDx, Inc. Prior to that, Mr. Moyes has served as the Chief Financial Officer of Myriad Genetics, Inc. from June 1996 until his retirement in November 2007, and served as Myriad's Vice President of Finance from July 1993 until July 2005. From 1991 to 1993, Mr. Moyes served as Vice President of Finance and Chief Financial Officer of Genmark, Inc. Mr. Moyes held various positions with the accounting firm of KPMG LLP from 1979 through 1991, most recently as a Senior Manager. He holds an M.B.A. degree from the University of Utah, a B.A. degree in economics from Weber State University, and is a Certified Public Accountant. Mr. Moyes has also served as a member of the Board of Trustees of the Utah Life Science Association from 1999 through 2006.
Barnhill, Gregory Mr. Gregory H. Barnhill has been a member of the Board of Osiris Therapeutics, Inc. since the completion of initial public offering in August 2006. Mr. Barnhill has served as a Partner and Member of the board of directors of Brown Advisory Securities, LLC since 2003. Mr. Barnhill is also a member of numerous philanthropic and corporate boards. From 1975 to 2003, Mr. Barnhill held various positions with Deutsche Bank Securities, Inc., most recently as Managing Director and Regional Manager, North American Equity Sales. He holds a B.A. degree in economics from Brown University. Mr. Barnhill holds NYSE/NASD licenses series 7, 63, 9 and 10 as well as life, health and variable annuities insurance licenses.

Basic Compensation

Name Fiscal Year Total
Friedli, Peter --
Mills, C. Randall 1,215,920
Jacoby, Philip 204,106
Debrabandere, Lode 388,664
Williams, Michelle 370,019
Gutzwiller, Felix --
Moyes, Jay --
Barnhill, Gregory --
As Of 30 Dec 2008

Options Compensation

Name Options Value
Friedli, Peter 0 0
Mills, C. Randall 600,000 0
Jacoby, Philip 3,125 45,594
Debrabandere, Lode 0 0
Williams, Michelle 0 0
Gutzwiller, Felix 0 0
Moyes, Jay 0 0
Barnhill, Gregory 0 0

Insider Trading

Name Shares Traded Price
MILLS CHARLES RANDAL 500 $12.23
DEBRABANDERE LODE 37,500 $12.49
DEBRABANDERE LODE 37,500 $6.84
MOYES JAY M 3,000 $18.60
BARNHILL GREGORY HURD 5,000 $18.60
GUTZWILLER FELIX 3,500 $18.60
FRIEDLI PETER 10,000 $18.60
CARMITCHEL HARRY E 7,000 $19.46
CARMITCHEL HARRY E 5,000 $20.35
FRIEDLI PETER 205,423 $12.17
VENTURETEC INC 189,681 $13.18
JACOBY PHILIP R JR 3,125 $0.40
FRIEDLI PETER 1,000,000 $0.00
FENDER EARL R 37,500 $6.84
CARMITCHEL HARRY E 7,500 $10.36
» Full list on Insider Trading
view people for: